Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study.

@article{Weitz2015TwoDO,
  title={Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study.},
  author={Jeffrey I. Weitz and Rupert M Bauersachs and Jan Beyer-Westendorf and Henri Bounameaux and Timothy Brighton and Alexander T. Cohen and Bruce L. Davidson and Gerlind Holberg and Ajay Kakkar and Anthonie W. A. Lensing and Martin H. Prins and Lloyd P Haskell and Bonno van Bellen and Peter Verhamme and Philip Stephen Wells and Paolo Prandoni},
  journal={Thrombosis and haemostasis},
  year={2015},
  volume={114 3},
  pages={
          645-50
        }
}
Patients with unprovoked venous thromboembolism (VTE) are at high risk for recurrence. Although rivaroxaban is effective for extended VTE treatment at a dose of 20 mg once daily, use of the 10 mg dose may further improve its benefit-to-risk ratio. Low-dose aspirin also reduces rates of recurrent VTE, but has not been compared with anticoagulant therapy. The EINSTEIN CHOICE study is a multicentre, randomised, double-blind, active-controlled, event-driven study comparing the efficacy and safety… 
View on PubMed
thieme-connect.de
46 Citations
Highly Influential Citations
1
Background Citations
6
Methods Citations
1

46 Citations

Citation Type

Citation Type

[EINSTEIN CHOICE: Comparison of rivaroxaban treatment and prophylactic doses with aspirin in the extended treatment of patients with venous thromboembolism].
  • C. Kaymaz
  • Medicine
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
  • 2017
TLDR
In patients with VTE in equipoise for extended anticoagulation, either a treatment dose or a prophylactic dose of rivaroxaban compared with ASA significantly reduced the risk of VTE recurrence without a significant increase in bleeding risk.
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin.
Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension.
Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies.
Venous thromboembolism (VTE) presents a continuing clinical burden to healthcare systems and there are patient groups for whom VTE management is challenging. Depending on the patient profile, the…
Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism.
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
TLDR
Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates.
Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism
TLDR
DOACs are effective and safe for the extended treatment of VTE, and may reduce the risk of all-cause mortality.
Risk of recurrent venous thromboembolism according to baseline risk factor profiles.
TLDR
Recurrence rates in patients with VTE provoked by minor persistent or minor transient risk factors were not significantly lower than that with unprovoked VTE, and such patients may also benefit from extended anticoagulation therapy.
Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
TLDR
Results of phase III trials evaluating direct oral anticoagulants for VTE treatment showed the DOACs were equally effective for prevention of recurrence, but were associated with less bleeding, and the management of bleeding was reviewed.
Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
TLDR
The quality of the evidence for recurrent VTE and all-cause mortality to moderate was downgraded to moderate owing to concerns arising from risks of selection and performance bias in individual studies, and risk of bias in the individual study was low.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 20 REFERENCES
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
TLDR
In key subgroups, including fragile patients, cancer patients, patients presenting with large clots, and those with a history of recurrent VTE, the efficacy and safety of rivaroxaban were similar compared with standard-therapy and was associated with a significantly lower rate of major bleeding.
Oral rivaroxaban for symptomatic venous thromboembolism.
TLDR
Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation.
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
TLDR
A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile.
Apixaban for extended treatment of venous thromboembolism.
TLDR
Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding.
Aspirin for preventing the recurrence of venous thromboembolism.
TLDR
Aspirin reduced the risk of recurrence when given to patients with unprovoked venous thromboembolism who had discontinued anticoagulant treatment, with no apparent increase in therisk of major bleeding.
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.
Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration
TLDR
Aspirin after anticoagulant treatment reduces the overall risk of recurrence by more than a third in a broad cross-section of patients with a first unprovoked VTE, without significantly increasing the risk of bleeding.
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
TLDR
Rivaroxaban started six to eight hours after surgery was more effective than enoxaparin started the previous evening in preventing symptomatic venous thromboembolism and all-cause mortality, without increasing major bleeding.
Low-dose aspirin for preventing recurrent venous thromboembolism.
TLDR
The results substantiate earlier evidence of a therapeutic benefit of aspirin when it is given to patients after initial anticoagulant therapy for a first episode of unprovoked venous thromboembolism and result in a significant reduction in the rate of major vascular events, with improved net clinical benefit.
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis.
TLDR
Rivaroxaban results in improved treatment satisfaction compared with enoxaparin/VKA among patients with DVT, particularly in reducing patient-reported anticoagulation burden.
...
1
2
...